Joshua Fitch, Senior Editor

Access to mental health care for youth living in rural areas presents several challenges. Jennifer Marr, DNP, APRN, CNP, PNP-C, explains how a mobile mental health clinic could expand care.

Tracie W. Kirkland, PhD, DNP, ANP-BC, PPCPNP, CPNP-BC, highlights the importance of awareness to the benefits of breastfeeding, and ways to rethink equitable breastfeeding using patient-centered care.

Tracie W. Kirkland, PhD, DNP, ANP-BC, PPCPNP, CPNP-BC, shares why she looks forward to networking at the 2024 NAPNAP National Conference on Pediatric Health Care, taking place from March 13-16, 2024, in Denver, Colorado.

Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, shares her thoughts and excitement for the 2024 NANAP National Conference on Pediatric Health Care, taking place in Denver, Colorado, from March 13-16, 2024.

In 2021, pediatric mental health conditions were associated with $31 billion in child spending and $59 billion in household spending, which made up 46.6% of all pediatric medical spending that year.

The approval is based on data from a phase 3, multicenter, randomized trial that evaluated patients aged 8 to 17 years with HeFH who had LDL-C levels of 130 mg / dL or greater who were being treated with lipid-lowering medications.

In the study period and among individuals aged 12 to 24 years, mental health-associated visits increased nearly 2-fold from 2006 to 2019.

Data from a pair of identical, phase 3, double-blind, randomized, and vehicle-controlled trials were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.

Though a small number of infants received nirsevimab in the analysis, results support existing nirsevimab recommendations to prevent serious RSV disease in infants.

Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, believes behavioral health is currently at the forefront of pediatric health care and explains how simple questions can lead to better care for a child.

According to the data, vaccination coverage in the United States has been lower in this influenza season compared to the previous season and to seasons before the COVID-19 pandemic.

The device is intended for anyone aged 18 years and up who do not use insulin or those without diabetes who want to learn how diet can impact blood sugar levels.

Scott Ceresnak, MD, explains ways AI technology could be useful when it comes to pediatric cardiology, though he states "big" research data is needed to generate pediatric specific algorithms.

The federal agency approved Perflutren Lipid Microsphere following positive data from 3 pediatric clinical trials.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Guidance now aligns with isolation recommendations for influenza and other respiratory illnesses.

Across all age groups polled, 49% of parents agreed that using headphones helped keep their child entertained.

Study authors of a paper published in The New England Journal of Medicine highlighting omalizumab for multiple common food allergies provided their comments regarding positive phase 3 data.

Scott Ceresnak, MD, explains smartwatch technology could be a great tool in detecting arrhythmias in children, however, given that algorithms in the technology were designed for adults, caution must be used as well.

"Collaboration can help us make more accurate diagnoses, develop more effective multimodal treatment plans, and monitor progress in many areas," said James Wallace, MD.

A poster presentation at AAAAI from the phase 3 PEOPLE Study revealed DBV712 treatment in children with peanut allergy has a favorable safety and tolerability profile.

Omalizumab was approved by the FDA on February 16, 2024 as the first and only FDA-approved medicine to reduce allergic reactions in patients with 1 or more food allergies.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Thomas Casale, MD, discusses phase 3 data presented at the 2024 AAAAI Meeting in Washington DC, highlighting neffy's efficacy in pediatric patients at risk for anaphylaxis.

Take this short quiz and test your knowledge of the American Academy of Pediatrics' clinical practice guideline to evaluate and treat children and adolescents with obesity.

Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.

The Rare Pediatric Disease Designation joins the Fast Track and Orphan Designations that have already been granted to AOC 1044.

A Prescription Drug User Fee Act (PDUFA) target action date of June 21, 2024, has been set by the FDA.

ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).